NCT05783453已完成不适用
CLINICAL EFFICACY OF EMOLLIENTS IN ATOPIC DERMATITIS PATIENTS: REDUCTION OF CRISES AND MAINTENANCE OF TREATMENT. STUDY UNDER NORMAL CONDITIONS OF USE AND DERMATOLOGICAL SUPERVISION
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 63
- 试验地点
- 1
- 主要终点
- Improvement of SCORAD Score
研究概览
简要总结
his was a monocentric, intra-individual study, that was performed in at least 45 valid cases (50% children ≥3 YO; 50% adults). Study duration was 168 days with five (5) visits (D0, D14, D28, D84 and D168) to the research center.
Primary objective
- Evaluation of the efficacy of LIPIKAR BAUME LIGHT AP+M in decrease the SCORAD in child and adult subjects with mild atopic dermatitis after 14 and 28 days under normal conditions of use;
- Evaluation of the efficacy of LIPIKAR BAUME LIGHT AP+M in maintenance the SCORAD value in child and adult subjects with mild atopic dermatitis after 84 and 168 days under normal conditions of use.
Secondary objective
- Evaluation of flares quantity and severity during 84 and 168 days of use;
- Clinical evaluation of the improvement of skin parameters such as erythema, oedema, oozing, excoriation, lichenification, dryness and desquamation of a lesional and non-lesional skin from the same individual site by dermatologist after 14, 28, 84 and 168 days;
- Self-assessment of the improvement of skin parameters such as itching, tingling, burning by subjects after 14, 28, 84 and 168 days;
- Evaluate the perceived efficacy, cosmeticity and acceptability through a subjective evaluation questionnaire after 14, 28, 84 and 168 days;
- Evaluation of the improvement in skin barrier function by the loss of transepidermic water through instrumental measurements with the Tewameter® equipment on AF and UAF after 14, 28, 84 and 168 days;
- Evaluation of the improvement of skin moisturizing through instrumental measurements with Corneometer® equipment on AF and UAF after 14, 28, 84 and 168 days;
- The folliculitis incidence after 14, 28, 84 and 168 days;
- Assessment of the improvement of the impact of quality of life through a DLQI (Dermatology Life Quality Index) questionnaire after 14, 28, 84 and 168 days;
- Assessment of global tolerance through clinical dermatological evaluation and reports performed by the subjects after using the product after 14, 28, 84 and 168 days.
- Evaluation of total body skin dryness improvement after 14, 28, 84 and 168 days.
- Illustrative clinical pictures of one or two affected areas.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 3 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Women or men, from 3 years old, being 50% children (≥3 years old ≤ 11 years and 11 months) and 50% adults;
- •All phototypes (a good balance between the phototypes is not mandatory, but all phototypes should be included);
- •Diagnosis of atopic dermatitis must meet Hanifin's criteria (at least 3 basic features and at least 3 minor features);
- •Subject with mild atopic dermatitis present for at least 6 months before inclusion (SCORAD at inclusion < 25);
- •Subjects that have an unchanged AD routine for at least 3 months, including to systematic use of topical or systemic antihistamines, topical or systemic corticoid, cyclosporin A and other immunosuppressant.
- •Subject able to use the study product at least once a day during all study.
- •Subject agreeing not to change their lifestyle during the study period (overbathing, being exposed to intense stress as change job, do a fast diet to loose weight...);
- •Subject agreeing to use only the study product and no other topical treatment for the duration of the study (usual topical or oral treatment for AD is allowed);
- •Subject capable of reading the documents presented to them, of adhering to the study regulations and accepting the limitations;
- •Subject available to follow the study;
- •Subject agreeing to participate and having signed the informed consent;
- •Subject available to be contacted by phone throughout the study.
排除标准
- •Breastfeeding, pregnant;
- •Subject presenting with another dermatological condition that could interfere with clinical evaluation;
- •Subject presenting a previous history of allergy to cosmetic products;
- •Subject having received any systemic treatment, including PUVA therapy for atopic dermatitis in the month prior to Day 0;
- •Subject having received phototherapy within 2 weeks before the first visit;
- •Subject who intend to excessively expose themselves to the sun during the study;
- •Subject known allergy to any component of the tested product (subjects will be asked if they have allergies to any ingredients and will be checked in the list if it is contained in the IP);
- •Subject who have used any experimental treatment within 2 weeks before the first visit;
- •Subject not presenting with the conditions needed to comply with the protocol;
- •Subject unable to give their informed consent;
- •Subject not available to follow the study in its entirety.
结局指标
主要结局
Improvement of SCORAD Score
时间窗: Day 168
Maintenance of SCORAD in child and adult subjects with mild atopic dermatitis after 14 and 28 days under normal conditions of use
次要结局
- Evolution of Quality of life over time(Day 156)
- Folliculitis(Day 156)
- Product acceptability(Day 156)
- Skin hydration(Day 156)
- Total body dryness(Day 156)
- Skin parameters(Day 156)
- Skin moisturizing(Day 156)
- local tolerance reporting(Day 156)
- Flares(Day 168)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Evaluation of clinical efficacy of autologous gamma-globulin therapy for the patients with recalcitrant atopic dermatitisDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0000549Ajou University Hospital20
已完成
不适用
Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic DermatitisDermatitis, AtopicNCT01948869Bayer35
已完成
4 期
Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic DermatitisDermatitis, AtopicNCT00667160Astellas Pharma Inc426
已完成
2 期
A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus HydrocortisoneDermatologic DiseaseNCT05607901Tanta University100
已完成
3 期
Study of 0417 Ointment in the Treatment of Atopic DermatitisAtopic DermatitisNCT01139450Fougera Pharmaceuticals Inc.899